



# RBC Life Science and Technology Fund

## Investment Objective

To provide long-term capital growth by investing primarily in equity securities of U.S. companies whose businesses relate to life sciences and technology and are expected to benefit from scientific and technological advances.

## Fund Details

Series	Load Structure	Currency	Fund Code
A	No Load	CAD	RBF274

Inception Date	July 1995
Total Fund Assets \$Mil	253.0
Series A NAV \$	17.06
Series A MER %	2.09
Benchmark	50% S&P 500 Health Care 50% S&P 500 Info Tech (measured in C\$)

Income Distribution	Annually
Capital Gains Distribution	Annually

Sales Status	Open
Min. Investment \$	500
Subsequent Investment \$	25


Fund Category	US Equity
---------------	-----------

Management Company	RBC Global Asset Management Inc.
--------------------	----------------------------------

Web Site	www.rbcgam.com
----------	----------------

## Portfolio Analysis as of December 31, 2017

### Asset Mix




	% Assets
Cash	3.2
Fixed Income	0.0
Canadian Equity	0.0
US Equity	95.2
International Equity	1.6
Other	0.0

### Top 25 Holdings

	% Assets
Apple Inc	9.9
Microsoft Corp	8.0
Alphabet Inc A	7.5
Facebook Inc A	5.1
Johnson & Johnson	3.8
UnitedHealth Group Inc	2.8
Visa Inc Class A	2.7
Cisco Systems Inc	2.5
Pfizer Inc	2.4
Intel Corp	2.2
Mastercard Inc A	1.9
Oracle Corp	1.8
AbbVie Inc	1.6
Broadcom Ltd	1.6
Amgen Inc	1.4
Accenture PLC A	1.4
Texas Instruments Inc	1.4
International Business Machines Corp	1.4
Merck & Co Inc	1.4
Adobe Systems Inc	1.4
NVIDIA Corp	1.3
Bristol-Myers Squibb Company	1.2
Salesforce.com Inc	1.2
PayPal Holdings Inc	1.2
Qualcomm Inc	1.1
Total % of Top 25 Holdings	68.0
Total Number of Stock Holdings	112
Total Number of Bond Holdings	0
Total Number of Other Holdings	3
<b>Total Number of Holdings</b>	<b>115</b>

### Equity Style



Value Blend Growth


### Equity Statistics

P/B Ratio	4.7
P/E Ratio	20.7
Avg. Mkt Cap. \$B	216.6

### Global Equity Sectors

	% Equity
Information Technology	67.0
Health Care	32.7
Industrials	0.3
Telecommunication Services	0.0
Energy	0.0
Materials	0.0
Consumer Discretionary	0.0
Consumer Staples	0.0
Financials	0.0
Utilities	0.0
Real Estate	0.0
Unclassified	0.0

## Performance Analysis as of December 31, 2017



	1 Mth	3 Mth	6 Mth	1 Yr	3 Yr	5 Yr	10 Yr	Since Incep.	Trailing Return %
	-2.9	6.1	9.0	22.1	13.8	22.8	11.2	5.5	Fund
	4 <sup>th</sup>	3 <sup>rd</sup>	2 <sup>nd</sup>	1 <sup>st</sup>	1 <sup>st</sup>	1 <sup>st</sup>	1 <sup>st</sup>	—	Quartile
	1411	1401	1367	1300	891	561	249	—	No. of Funds in Category



# RBC Life Science and Technology Fund

## Management Overview

### Manager Bios

#### Rob Cavallo

##### RBC Global Asset Management Inc.

Rob is a Portfolio Manager with the North American equities team. Rob joined the firm in 2012 as a Global equities analyst with a focus on analyzing companies within the Health Care and Consumer sectors. Rob earned a Bachelor of Commerce degree at the University of Toronto and is a CFA charterholder.

#### Marcello Montanari

##### RBC Global Asset Management Inc.

Marcello Montanari is Vice President and Senior Portfolio Manager, North American Equities. Marcello began his career in the investment industry in 1992. He earned a Bachelor of Commerce degree in finance from Concordia University and is a CFA charterholder.

### Performance Analysis Cont'd as of December 31, 2017

Distributions (\$)/Unit	2017*	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
Total Distributions	—	—	—	—	—	—	—	—	—	—	—
Interest	—	—	—	—	—	—	—	—	—	—	—
Dividends	—	—	—	—	—	—	—	—	—	—	—
Capital Gains	—	—	—	—	—	—	—	—	—	—	—
Return Of Capital	—	—	—	—	—	—	—	—	—	—	—

Best/Worst Periods %	Ended	1 Yr	Ended	3 Yr	Ended	5 Yr	Ended	10 Yr
Best	2-2000	138.3	2-2000	48.4	8-2000	34.7	11-2017	11.3
Worst	9-2001	-61.9	2-2003	-37.9	8-2005	-23.8	8-2010	-14.1
Average		8.7		8.0		5.9		1.8
No. of Periods		258		234		210		150
Pct. Positive		65.5		58.1		50.5		48.7

\* Final distribution attribution (interest, dividends, capital gains and return of capital) for 2017 will be reflected with January month-end profiles.

### Quarterly Commentary as at December 31, 2017

Overweight allocation to the Information Technology (IT) sector contributed positively to performance. However, security selection was an offset with key contributors to the weakness including Celgene, Boston Scientific and Shopify.

IT stocks continued their strong rally during Q4 and finished as the second strongest sector on a relative basis behind Consumer Discretionary. Health Care sector performance contributed positive absolute returns.

The IT sector was led by semiconductor companies such as Intel, Qualcomm and Texas Instruments, communications companies such as Cisco and software makers Microsoft and Adobe. Hardware performance improved as Apple recovered after some weakness in Q3. Semiconductor outperformance was in part helped by an announced takeover offer from Broadcom to Qualcomm in what would mark one of the largest transactions in the history of the sector. To date, Qualcomm has rebuffed the offer but the pursuit continued as of the end of 2017.

Health Care experienced solid relative performance in the U.S. for the full calendar year,

though was a relative underperformer during Q4. The weakness was largely driven by biotechnology and pharmaceuticals. Two of the larger companies within the sector, Celgene and Merck, were the main culprits with the stocks falling significantly. On the positive side, Medical Equipment & Supplies such as Align Technology and Abbott as well as Health Insurers such as Anthem and UnitedHealth continued to be strong performers.

The outlook for the IT sector continues to strengthen given the passage of U.S. tax reform, which will enable companies to more easily bring back cash held outside the U.S., and expectations of higher capital spending. However, IT stocks have had a strong run and could be susceptible to declines if economic conditions are not optimal.

Uncertainty around potential legislative changes to Obamacare's drug-reimbursement process seems lower than at the beginning of 2017. The easing of this risk, along with a possible acceleration in the level of mergers and acquisitions, particularly in the biotechnology industry, could boost the performance of the Health Care sector in 2018.



# RBC Life Science and Technology Fund

## Disclosure

RBC Funds, BlueBay Funds, PH&N Funds and RBC Corporate Class Funds are offered by RBC Global Asset Management Inc. and distributed through authorized dealers.

Commissions, trailing commissions, management fees and expenses all may be associated with mutual fund investments. Please read the prospectus or Fund Facts document before investing. Except as otherwise noted, the indicated rates of return are the historical annual compounded total returns including changes in unit value and reinvestment of all distributions and do not take into account sales, redemption, distribution or optional charges or income taxes payable by any unitholder that would have reduced returns. Mutual funds are not guaranteed or covered by the Canadian Deposit Insurance Corporation or by any other government deposit insurer. For money market funds, there can be no assurances that the fund will be able to maintain its net asset value per unit at a constant amount or that the full amount of your investment in the fund will be returned to you. The value of mutual funds change frequently and past performance may not be repeated.

This document has been compiled by RBC Global Asset Management Inc. (RBC GAM) from sources believed to be reliable, but no representations or warranty, express or

implied, are made by RBC GAM, its affiliates or any other person as to its accuracy, completeness or correctness. All opinions and estimates constitute RBC GAM's judgment as of the date of this document, are subject to change without notice and are provided in good faith but without legal responsibility. The Top Ten/25 Holdings may change due to ongoing portfolio transactions within the fund. The Prospectus and other information about the underlying investment funds are available at [www.sedar.com](http://www.sedar.com).

MER (%) for RBC Funds, PH&N Funds and BlueBay Funds is based on actual expenses for the half-year period, January 1 to June 30, 2017, expressed on an annualized basis.

MER (%) for RBC Corporate Class Funds is based on actual expenses for the half-year period, April 1, to September 30, 2017, expressed on an annualized basis.

Series H and Series I are not available for purchase by new investors. Existing investors who hold Series H or Series I units can continue to make additional investments into the same series of the funds they hold.

Graphs are only used to illustrate the effects of the compound growth rate and do not reflect future values of any fund or returns on investment of any fund.

The fund profile is provided for informational purposes only. Particular investments and/or trading strategies should be evaluated relative to each individual's investment objectives. The information contained in the fund profile is not, and should not be construed as, investment or tax advice. You should not act or rely on the information contained in the fund profile without seeking the advice of an appropriate professional advisor.

Quartile rankings are determined by Morningstar Research Inc., an independent research firm, based on categories maintained by the Canadian Investment Funds Standards Committee (CIFSC). Quartile rankings are comparisons of the performance of a fund to other funds in a particular category and are subject to change monthly. The quartiles divide the data into four equal segments expressed in terms of rank (1, 2, 3 or 4). This is the Morningstar quartile ranking of Series A and F units of the Fund as of December 31, 2017.

® / ™ Trademark(s) of Royal Bank of Canada. Used under licence. © RBC Global Asset Management Inc. 2018